Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 866 entries
View as:

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Phase: N/A Priority: Normal
NCT ID: NCT01969682 Org: User:
Start: 04/30/14 End: 05/31/14 Due: 05/31/15

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05909553 Org: User:
Start: 06/15/23 End: 09/22/23 Due: 09/22/24

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Phase: N/A Priority: Normal
NCT ID: NCT01939197 Org: User:
Start: 08/30/13 End: 10/25/16 Due: 10/25/17

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT05005403 Org: User:
Start: 11/01/21 End: 07/31/27 Due: 07/31/28

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT04435600 Org: User:
Start: 07/14/20 End: 10/15/24 Due: 10/15/25

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT04030962 Org: User:
Start: 03/04/20 End: 03/18/22 Due: 03/18/23

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06390722 Org: User:
Start: 05/23/24 End: 07/08/26 Due: 07/08/27

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04908475 Org: User:
Start: 06/09/21 End: 04/20/23 Due: 04/20/24

Study Of Diabetic Nephropathy With Atrasentan

Phase: N/A Priority: Normal
NCT ID: NCT01858532 Org: User:
Start: 05/17/13 End: 03/29/18 Due: 03/29/19

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04380142 Org: User:
Start: 10/19/20 End: 09/29/21 Due: 09/29/22

A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT04758117 Org: User:
Start: 02/04/21 End: 07/26/23 Due: 07/26/24

Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

Phase: N/A Priority: Normal
NCT ID: NCT02092389 Org: User:
Start: 07/31/14 End: 03/31/16 Due: 03/31/17

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02601885 Org: User:
Start: 10/18/16 End: 04/20/18 Due: 04/20/19

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

Phase: N/A Priority: Normal
NCT ID: NCT05444972 Org: User:
Start: 08/23/22 End: 11/14/23 Due: 11/14/24

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02033551 Org: User:
Start: 12/31/13 End: 09/30/16 Due: 09/30/17

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02068222 Org: User:
Start: 04/30/14 End: 03/31/15 Due: 03/31/16

A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)

Phase: N/A Priority: Normal
NCT ID: NCT04750213 Org: User:
Start: 02/12/21 End: 08/31/25 Due: 08/31/26

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03255382 Org: User:
Start: 08/22/17 End: 07/06/18 Due: 07/06/19

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02642432 Org: User:
Start: 12/07/15 End: 02/10/17 Due: 02/10/18

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02049138 Org: User:
Start: 01/24/14 End: 07/29/21 Due: 07/29/22

Chronic Plaque Psoriasis (Ps) Registry

Phase: N/A Priority: Normal
NCT ID: NCT00799877 Org: User:
Start: 09/26/08 End: 02/13/23 Due: 02/13/24

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Phase: N/A Priority: Normal
NCT ID: NCT02672852 Org: User:
Start: 02/29/16 End: 07/26/18 Due: 07/26/19

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Phase: N/A Priority: Normal
NCT ID: NCT03999801 Org: User:
Start: 05/31/19 End: 12/31/28 Due: 12/31/29

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02365649 Org: User:
Start: 03/17/15 End: 08/03/17 Due: 08/03/18

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Phase: N/A Priority: Normal
NCT ID: NCT05125302 Org: User:
Start: 01/13/22 End: 05/31/26 Due: 05/31/27